Key Points
- Dennis Cho sold 324 shares of Twist Bioscience on Dec. 22 at an average price of $34.56 (~$11,197), leaving him with 144,680 shares (a 0.22% reduction); he made several larger sales in Oct.–Nov. as well.
- Twist shares opened down about 3.5%, the company has a market cap of ~$2.07 billion and a negative P/E, and it reported an EPS miss for the quarter (‑$0.45 vs. consensus ‑$0.40) while posting $99.01M in revenue.
- Analyst coverage is mixed-to-positive: eight Buys and two Sells yield a MarketBeat consensus rating of “Moderate Buy” with a consensus price target of $44.88.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 324 shares of the firm's stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $34.56, for a total value of $11,197.44. Following the transaction, the insider directly owned 144,680 shares of the company's stock, valued at $5,000,140.80. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Dennis Cho also recently made the following trade(s):
- On Monday, November 3rd, Dennis Cho sold 1,019 shares of Twist Bioscience stock. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52.
- On Thursday, October 30th, Dennis Cho sold 6,515 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total transaction of $204,831.60.
- On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total transaction of $124,768.44.
Twist Bioscience Trading Down 3.5%
Twist Bioscience stock opened at $33.84 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -25.83 and a beta of 2.24. The firm's 50 day moving average price is $31.09 and its two-hundred day moving average price is $31.21. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $55.33.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. On average, research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Barclays increased their price objective on Twist Bioscience from $37.00 to $39.00 and gave the stock an "overweight" rating in a research note on Monday, December 15th. Stephens started coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an "overweight" rating and a $41.00 price target for the company. Evercore ISI lowered their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $44.88.
Get Our Latest Stock Analysis on TWST
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. EdgePoint Investment Group Inc. grew its holdings in Twist Bioscience by 71.1% during the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company's stock valued at $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Twist Bioscience by 186.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after buying an additional 1,588,587 shares during the period. Artisan Partners Limited Partnership grew its stake in Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company's stock valued at $180,403,000 after buying an additional 1,349,867 shares during the last quarter. Millennium Management LLC grew its stake in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company's stock valued at $50,479,000 after buying an additional 1,080,722 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its holdings in Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company's stock worth $23,113,000 after acquiring an additional 567,481 shares during the period.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
